Regeneron Pharmaceuticals holds recent Real Value of $346.28 per share. The prevailing price of the company is $286.15. At this time the company appears to be undervalued. This module determines value of Regeneron Pharmaceuticals from analyzing the company fundamentals such as Operating Margin of
32.08%, Return On Equity of 24.43% and Shares Outstanding of 107.98M as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.
September 19, 2019
Regeneron Pharmaceuticals is very steady asset. Calculation of real value of Regeneron Pharmaceuticals is based on 3 months time horizon. Increasing Regeneron Pharmaceuticals time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Valuation Drivers Correlation
|Click cells to compare fundamentals||View All Correlations|
Regeneron Pharmaceuticals Market CapRegeneron Pharmaceuticals is rated third in market capitalization category among related companies. Market capitalization of Biotechnology industry is at this time estimated at about 179.38 Billion. Regeneron Pharmaceuticals retains roughly 31.4 Billion in market capitalization claiming about 18% of stocks in Biotechnology industry.
|Horizon||30 Days Login to change|
Regeneron Pharmaceuticals is rated third in price to earning category among related companies. It is rated third in price to book category among related companies fabricating about 0.20 of Price to Book per Price to Earning. The ratio of Price to Earning to Price to Book for Regeneron Pharmaceuticals is roughly 4.96
|Price to Earning ( times )|
|Price to Book ( times )|